Wells Fargo & Company Astria Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 16,339 shares of ATXS stock, worth $193,943. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,339
Previous 17,039
4.11%
Holding current value
$193,943
Previous $239,000
38.08%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ATXS
# of Institutions
103Shares Held
49.4MCall Options Held
27.6KPut Options Held
29.7K-
Perceptive Advisors LLC New York, NY6.49MShares$77 Million1.71% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.04MShares$59.9 Million0.69% of portfolio
-
Vr Adviser, LLC New York, NY3.61MShares$42.8 Million3.6% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$42.2 Million6.42% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$41.8 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $180M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...